Plasma Fractionation Market To Reach $58.24 Billion By 2030

Plasma Fractionation Market Growth & Trends

The global plasma fractionation market size is estimated to reach USD 58.24 billion by 2030, registering to grow at a CAGR of 8.5% from 2025 to 2030 according to a new report by Grand View Research, Inc. The major factors driving the market growth are the rising prevalence of respiratory illnesses globally, blood-related diseases, and an aging population that is prone to a variety of rare disorders. These are the main drivers of market expansion. In addition, the rise in the prevalence of rare disorders that call for plasma therapy or derivatives also supplemented the market growth.

The global market is also expanding due to the increased use of immunoglobulins as well as alpha-1-antitrypsin in various areas of research around the world. Another important factor for the expansion of the market is the rise in blood collection facilities globally. For instance, as per the WHO, as of May 2022, over 118 million blood donations were collected across the globe, thus increasing the plasma supply gradually. Additionally, supportive government initiatives to raise public awareness about the usage of plasma-derived products also serve as a major driver of the global market's expansion.

Blood plasma transfusions are one of the cutting-edge treatments for COVID-19 infection. For instance, in August 2020, the US Food and Drug Administration (USFDA) granted the convalescent plasma treatment of COVID-19 an emergency use authorization (EUA). Additionally, in February 2021, it published an amended directive for the plasma EUA for COVID-19. As a result, the usage of plasma fractionation technologies is projected to increase during the COVID-19 pandemic.

The growing demand for personalized medications has increased R&D spending, and technological advancements in plasma components such as immune serum globulin, which have advantages such as higher yield, lower cost, and faster throughput, are driving market growth. On the other hand, immunoglobulins generated from plasma are being employed more frequently for a variety of clinical conditions, including autoimmune and inflammatory illnesses. Therapies including Ceruloplasmin, IgA, and Plasmin have received significant funding from the plasma fractionation sector. Additionally, the industry will receive a boost from booming investments in innovation and technology developments that result in efficient and affordable methods for fractionating proteins. thus, propelling the market's growth.

For companies operating market-related businesses, the market offers a lot of opportunities. In addition, the global and regional market participants are actively implementing organic and inorganic development strategies as a result of the market's favorable expansion. As a result, it is anticipated that the market will draw more notable investments during the forecast period. For instance, in January 2022, the eighth plasma collection facility in the Czech Republic was opened by Biotest AG. The national public health authority, SUKL, granted the company an operating license for these centers.

 Request a free sample copy or view report summary: Plasma Fractionation Market Report

Plasma Fractionation Market Report Highlights

• The immunoglobulins segment dominated the market in terms of revenue share of 63.2% in 2024 and is anticipated to grow at the fastest CAGR of 9.1%. fueled by its widespread use in treating immune deficiencies, autoimmune diseases, and neurological disorders.

• The chromatography segment dominated the market and accounted for a 33.7% share in 2024. The utilization of industrial-scale chromatographic fractionation as well as purification techniques for plasma fractionation has increased recently.

• The neurology segment held the largest revenue share of 30.0% in 2024, driven by the increasing recognition of plasma-derived therapies for neurological disorders. Conditions such as multiple sclerosis, Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy are increasingly being treated with therapies like intravenous immunoglobulin (IVIg) and plasmapheresis.

• The hospitals and clinics dominated the market with the largest revenue share of 53.4% in 2024 and are expected to grow at the fastest CAGR of 9.0% over the forecast period. This is driven by the increasing demand for plasma-derived therapies in various medical applications.

Plasma Fractionation Market Segmentation

Grand View Research has segmented the global plasma fractionation market based on product, method, application, end-use, and region:

Plasma Fractionation Product Outlook (Revenue, USD Billion, 2018 - 2030)

• Albumin

• Immunoglobulins

  • Intravenous immunoglobulins

  • Subcutaneous immunoglobulins

  • Other immunoglobulins

• Coagulation Factors

  • Factor VIII

  • Factor IX

  • VON WILLEBRAND factor

  • Prothrombin complex concentrates

  • Fibrinogen concentrates

  • Others

• Protease inhibitors

• Others

Plasma Fractionation Method Outlook (Revenue, USD Billion, 2018 - 2030)

• Centrifugation

• Depth Filtration

• Chromatography

• Others

Plasma Fractionation Application Outlook (Revenue, USD Billion, 2018 - 2030)

• Neurology

• Hematology

• Oncology

• Immunology

• Pulmonology

• Others

Plasma Fractionation End-use Outlook (Revenue, USD Billion, 2018 - 2030)

• Hospitals & Clinics

• Clinical Research

• Others

Plasma Fractionation Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• MEA

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Plasma Fractionation Market

• Grifols S.A.

• CSL Limited

• Takeda Pharmaceutical Company Limited

• Octapharma AG

• Kedrion S.p.A

• LFB S.A.

• Biotest AG

• Sanquin

• Bio Products Laboratory Ltd.

• Intas Pharmaceuticals Ltd